Abstract
Amphotericin B causes reversible concentration-dependent loss of intracellular potassium in vitro and hyperkalemic ventricular arrhythmias in dogs. Hyperkalemic ventricular arrhythmias associated with amphotericin B infusion have not been well documented in humans. Ventricular fibrillation with progressive hyperkalemia (up to 8 to 8.4 meq/liter) occurred twice in an anuric patient during rapid infusion of high-dose amphotericin B (1.4 mg/kg over 45 min). The peak amphotericin B concentration in serum at the end of infusion was 6.7 micrograms/ml. Prolonged infusion (3 h) and concurrent hemodialysis each prevented the development of hyperkalemia and ventricular arrhythmia. In two anuric patients receiving 4-h infusions of amphotericin B during dialysis (0.7 and 1.0 mg/kg), peak amphotericin B concentrations in serum were lower, 1.6 +/- 0.1 and 2.7 +/- 0.7 micrograms/ml, respectively; serum potassium levels were maintained in the normal range; and venous access for outpatient therapy was convenient. Peak concentrations of amphotericin B in serum were also lower (1.7 +/- 0.7 micrograms/ml) in eight patients with normal renal function who received lower doses (0.7 +/- 0.2 mg/kg) over 45 min; there were only slight increases in the serum potassium level (from 3.9 +/- 0.9 to 4.4 +/- 0.6 meq/liter, P less than 0.05). We recommend that rapid infusion of amphotericin B not be used in patients with impaired potassium excretion unless accompanied by hemodialysis and careful potassium monitoring.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bindschadler D. D., Bennett J. E. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis. 1969 Oct;120(4):427–436. doi: 10.1093/infdis/120.4.427. [DOI] [PubMed] [Google Scholar]
- Block E. R., Bennett J. E., Livoti L. G., Klein W. J., Jr, MacGregor R. R., Henderson L. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. Ann Intern Med. 1974 May;80(5):613–617. doi: 10.7326/0003-4819-80-5-613. [DOI] [PubMed] [Google Scholar]
- Craven P. C., Ludden T. M., Drutz D. J., Rogers W., Haegele K. A., Skrdlant H. B. Excretion pathways of amphotericin B. J Infect Dis. 1979 Sep;140(3):329–341. doi: 10.1093/infdis/140.3.329. [DOI] [PubMed] [Google Scholar]
- Drazin R. E., Lehrer R. I. Rubidium release: a rapid and sensitive assay for amphotericin B. J Infect Dis. 1976 Sep;134(3):238–244. doi: 10.1093/infdis/134.3.238. [DOI] [PubMed] [Google Scholar]
- Feldman H. A., Hamilton J. D., Gutman R. A. Amphotericin B therapy in an anephric patient. Antimicrob Agents Chemother. 1973 Sep;4(3):302–305. doi: 10.1128/aac.4.3.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fields B. T., Jr, Bates J. H., Abernathy R. S. Effect of rapid intravenous infusion on serum concentrations of amphotericin B. Appl Microbiol. 1971 Oct;22(4):615–617. doi: 10.1128/am.22.4.615-617.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hoeprich P. D. Chemotherapy of systemic fungal diseases. Annu Rev Pharmacol Toxicol. 1978;18:205–231. doi: 10.1146/annurev.pa.18.040178.001225. [DOI] [PubMed] [Google Scholar]
- McCurdy D. K., Frederic M., Elkinton J. R. Renal tubular acidosis due to amphotericin B. N Engl J Med. 1968 Jan 18;278(3):124–130. doi: 10.1056/NEJM196801182780302. [DOI] [PubMed] [Google Scholar]
- Siegel E. B. Measurement of polyene antibiotic-mediated erythrocyte damage by release of hemoglobin and radioactive chromium. Antimicrob Agents Chemother. 1977 Apr;11(4):675–678. doi: 10.1128/aac.11.4.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tarala R. A., Smith J. D. CKryptococcosis treated by rapid infusion of amphotericin B. Br Med J. 1980 Jul 5;281(6232):28–28. doi: 10.1136/bmj.281.6232.28. [DOI] [PMC free article] [PubMed] [Google Scholar]